← Back to Search

Antisense Oligonucleotide

IONIS-AGT-LRx for Heart Failure (ASTRAAS-HF Trial)

Phase 2
Waitlist Available
Research Sponsored by Ionis Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Females must be non-pregnant and non-lactating and of non- childbearing potential.
An angiotensin-converting-enzyme inhibitor (ACEi), or angiotensin II receptor blockers (ARBs) or sacubitril/valsartan (mandatory)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 169
Awards & highlights

ASTRAAS-HF Trial Summary

This trial is testing a new drug to see if it can lower angiotensinogen levels in people with heart failure.

Eligible Conditions
  • Heart Failure

ASTRAAS-HF Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

ASTRAAS-HF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 169
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to day 169 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent Change in Plasma AGT Concentration From Baseline to Study Day 85
Secondary outcome measures
Absolute Level of NT-proBNP
Absolute Level of Plasma AGT
Change in NT-proBNP From Baseline to Each Scheduled, Post-Baseline Visit
+3 more

ASTRAAS-HF Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: IONIS-AGT-LRxExperimental Treatment1 Intervention
IONIS-AGT-LRX by subcutaneous injection once-weekly
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo by subcutaneous injection once-weekly
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IONIS-AGT-LRx
2021
Completed Phase 2
~240

Find a Location

Who is running the clinical trial?

Ionis Pharmaceuticals, Inc.Lead Sponsor
145 Previous Clinical Trials
15,193 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the enrollment period for this experiment currently open?

"Clinicaltrials.gov states that this research initiative, which was launched on June 8th 2021 and later updated on November 23rd 2022, is no longer recruiting patients. That being said, over 700 other clinical trials are still actively seeking volunteers at the present time."

Answered by AI

How could patients be affected by the administration of IONIS-AGT-LRx?

"Taking into account the Phase 2 nature of this trial, there is a moderate amount of evidence verifying IONIS-AGT-LRx's safety; thus, our team at Power has assigned it a score of 2."

Answered by AI

What is the current scope of this trial's implementation?

"In addition to Michigan Heart in Ypsilanti, Arkansas Cardiology in Little Rock, and Medstar Washington Hospital Center in DC, this trial is accepting patients from other 13 locations."

Answered by AI

Is this clinical trial limited to people under 25 years of age or can older individuals also participate?

"This research requires participants to be between 18 and 80 years of age. Alternatively, there are 22 clinical studies specifically targeting those younger than 18 while 690 trials focus on older demographics above the age of 65."

Answered by AI

Is enrollment open for this research study?

"This clinical trial requires 72 participants aged between 18 and 80 who have been diagnosed with heart failure. Women must not be pregnant, lactating or potentially able to conceive while men need to either undergo a surgical sterilization process, abstain from sexual relations or use contraception when engaging in intercourse with women of child-bearing potential. Additionally, all subjects should be taking beta-blockers unless contraindicated or not tolerated by the patient's body."

Answered by AI
~19 spots leftby Mar 2025